[Lotus] Subsidiary Alvogen Korea Acquires Marketing Authorization for Product 'Matterhorn' in the Korean Market from OM PHARMA SA
Lotus Pharmaceutical (Taiwan) announced that its subsidiary, Alvogen Korea, has decided to acquire intellectual property rights, marketing authorizations, and product technology related to 'Matterhorn' for the Korean market from OM PHARMA SA for 69 million USD.
📋 Article Processing Timeline
- 📰 Published: May 21, 2026 at 09:00
- 🔍 Collected: May 22, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 22, 2026 at 08:03 (3 min after Collected)
1. Name and Nature of Target Object: Intellectual property rights, marketing authorizations, and product technology for the product 'Matterhorn' sold in the Korean market by OM PHARMA SA.
2. Date of Occurrence: May 21, 2026.
3. Board Approval Date: May 21, 2026.
5. Transaction Quantity, Unit Price, and Total Amount: 69 million USD.
6. Counterparty: OM PHARMA SA (Not a related party).
11. Payment Terms: Based on contractual conditions.
12. Basis for Decision: Approved by the Board of Directors after considering the valuation report provided by an independent expert.
17. Objective of Acquisition: Optimization of product portfolio.
20. Audit Committee Approval Date: May 20, 2026.
28. Source of Funding: Own funds and bank loans.
30. Other: The transaction amount is calculated based on the Taiwan Bank exchange rate on May 19, 2026, at 1 USD to 31.65 TWD.
2. Date of Occurrence: May 21, 2026.
3. Board Approval Date: May 21, 2026.
5. Transaction Quantity, Unit Price, and Total Amount: 69 million USD.
6. Counterparty: OM PHARMA SA (Not a related party).
11. Payment Terms: Based on contractual conditions.
12. Basis for Decision: Approved by the Board of Directors after considering the valuation report provided by an independent expert.
17. Objective of Acquisition: Optimization of product portfolio.
20. Audit Committee Approval Date: May 20, 2026.
28. Source of Funding: Own funds and bank loans.
30. Other: The transaction amount is calculated based on the Taiwan Bank exchange rate on May 19, 2026, at 1 USD to 31.65 TWD.
FAQ
Why did Lotus Pharmaceutical carry out this transaction?
To optimize its product portfolio and strengthen its business foundation in the South Korean market.
What is the market potential for this product?
While specific details have not been released, given Lotus Pharmaceutical's strategic acquisition, the company likely anticipates growth potential.
How does this transaction affect investors?
It is viewed as part of the company's sustainable growth strategy and is expected to improve the quality of its portfolio.